Chronic Myeloid Leukemia
Analysis of BCR/ABL transcripts in healthy individuals
Authors: J.A. Boquett1, J.R.P. Alves2 and C.E.C. de Oliveira3
The chimeric oncogene BCR/ABL, which is the product of reciprocal translocation between chromosomes 9 and 22, is a known molecular marker of chronic myeloid leukemia (CML), and is related to the major factors involved in leukemogenesis. Some previous studies have also reported the presence of this oncogene in peripheral blood cells of healthy individuals... Read More»
- Genet. Mol. Res. 12(4):
- 2013.October.24.8
- DOI:
- 10.4238/2013.October.24.8
Study on the treatment of the p15 gene combined with Bcr-abl-specific siRNA and STI571 for chronic myeloid leukemia
Authors: W. Wang, Y. Du, N.-N. Li, F.-F. Lv and G.-Q. Lin
The aim of this study was to investigate the effect of the p15 gene combined with Bcr-abl-specific siRNA and STI571 on the proliferation, cell cycle and apoptosis of K562 chronic myeloid leukemia cells. Using the gene sequence results, we amplified the p15 gene from normal peripheral blood by RT-PCR, and constructed a p15-pcDN.. Read More»
- Genet. Mol. Res. 13(2):
- http://dx.doi.org/2014.May.30.4
- DOI:
- http://dx.doi.org/10.4238/2014.May.30.4
Multidrug resistance gene (MDR1) polymorphisms may not be directly associated with response to imatinib in chronic myeloid leukemia
Authors: J.L. Wang, H.J. Liu, F. Li, W.Y. Yang, J.M. Wang, S.F. Tan and Q. Wang
Our study aimed to investigate the association between multidrug resistance (MDR1) gene polymorphisms and the response to imatinib (IM) in chronic myeloid leukemia (CML). An electronic databases in PubMed, Cochrane Library, Wanfang, China National Knowledge Infrastructure, and VIP were searched using combinations of k.. Read More»
- Genet. Mol. Res. 14(4):
- 2015.November.24.4
- DOI:
- 10.4238/2015.November.24.4
Association between methylene tetrahydrofolate reductase and glutathione S-transferase M1 gene polymorphisms and chronic myeloid leukemia in a Brazilian population
Authors: G.S. Lordelo, A.L. Miranda-Vilela, A.K. Akimoto, P.C.Z. Alves, C.O. Hiragi, A. Nonino, M.B. Daldegan, M.N. Klautau-Guimar�£es and C.K. Grisolia
Chronic myeloid leukemia is a hematopoietic stem cell disorder that causes uncontrolled proliferation of white blood cells. Although the clinical and biological aspects are well documented, little is known about individual susceptibility to this disease. We conducted a case-control study analyzing the prevalence of the polymor.. Read More»
- Genet. Mol. Res. 11(2):
- 2012.April.19.6
- DOI:
- 10.4238/2012.April.19.6
BCR-ABL1 transcript types showed distinct laboratory characteristics in patients with chronic myeloid leukemia
Authors: A.P. Vasconcelos, I.F. Azevedo, F.C.B.C. Melo, W.B. Neves, A.C.A.C. Azevedo and R.A.M. Melo
In chronic myeloid leukemia (CML) two main types of messenger RNA (e14a2 and e13a2) can be produced by BCR-ABL1 gene rearrangement. Due to conflicting results, the clinical value of these transcripts remains controversial. The aim of this study was to identify associations of e14a2 and e13a2 transcripts with laboratory variabl.. Read More»
- Genet. Mol. Res. 16(2):
- gmr16029541
- DOI:
- 10.4238/gmr16029541
Quantitative real-time polymerase chain reaction as an efficient molecular tool for detecting minimal residual disease in Moroccan chronic myeloid leukemia patients
Authors: A. Moumen, H. Dehbi, D. Kottwitz, M. El Amrani,N. Bouchoutrouch, H. El Hadi, A. Quessar, S. Benchekroun,S. Nadifi and H. Sefrioui
Chronic myeloid leukemia (CML) is characterized by BCR-ABL translocation and an increased number and migration of immature myeloid cells into the peripheral blood. The detection limit of the BCR-ABL transcript, particularly after treatment, is controversial. In the present study, we used quantitative real-time reverse transcription-polymerase chain reacti.. Read More»
- Genet. Mol. Res. 14(1):
- 2015.February.6.8
- DOI:
- 10.4238/2015.February.6.8
Discovery of somatic mutations in the progression of chronic myeloid leukemia by whole-exome sequencing
Authors: Y. Huang, J. Zheng, J.D. Hu, Y.A. Wu, X.Y. Zheng, T.B. Liu and F.L. Chen
We performed whole-exome sequencing in samples representing accelerated phase (AP) and blastic crisis (BC) in a subject with chronic myeloid leukemia (CML). A total of 12.74 Gb clean data were generated, achieving a mean depth coverage of 64.45 and 69.53 for AP and BC samples, respectively, of the target region. A total of 148.. Read More»
- Genet. Mol. Res. 13(1):
- 2014.February.19.5
- DOI:
- 10.4238/2014.February.19.5
Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia
Authors: Jos�© Alexandre Rodrigues de Lemos, Ciane Martins de Oliveira, Ana Carolina Costa Scerni, Alessandra Q. Bentes, Ana Cristina Beltr�£o, I�ª Regina G. Bentes, Tereza Cristina Azevedo and Luciana Maria Cunha Maradei-Pereira
Chronic myeloid leukemia (CML) originates from the hematopoietic stem cell and is characterized by the reciprocal translocation t(9;22)(q34;q11), which results in the BCR-ABL fusion gene on chromosome 22q-, also known as the Philadelphia chromosome. This chimeric gene codes for a cytoplasmic protein with constitutive tyrosinek.. Read More»
- Genet. Mol. Res. 4(4):
Response to treatment with imatinib mesylate in previously treated chronic-phase chronic myeloid leukemia patients in a hospital in Brazil
Authors: C.A.P. Silveira, M.B. Daldegan and I. Ferrari
We analyzed the results of treatment with imatinib mesylate in 70 patients with chronic-phase chronic myeloid leukemia who had previously been treated (with second-line or higher imatinib), many of them in a late chronic phase. The median follow-up period was 60.5 months (range 3-100 months). Our objective was to assess the ef.. Read More»
- Genet. Mol. Res. 10(3):
- vol10-3gmr1073
- DOI:
- 10.4238/vol10-3gmr1073
Philadelphia-negative chromosomal evolution during treatment for chronic myeloid leukemia
Authors: H.-H. Hsiao, Y.-C. Liu, C.-P. Lee, C.-S. Chang and S.-F. Lin
Chromosome evolution is one of the major mechanisms of disease progression and resistance in chronic myeloid leukemia (CML) patients. However, the clinical significance of chromosomal evolution in the Philadelphia (Ph)-negative clone during therapy is not fully understood. We evaluated 94 CML patients in the chronic phase of C.. Read More»
- Genet. Mol. Res. 11(1):
- http://dx.doi.org/2012.February.10.2
- DOI:
- http://dx.doi.org/10.4238/2012.February.10.2